Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387265 · ClinicalTrials.gov registry record · Phase 1
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by CytomX Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT05387265 is a Phase 1 study that was terminated before completion, run by CytomX Therapeutics. The registered enrollment target is 83 participants.
The verdict
NCT05387265, a Phase 1 study, was terminated before completion, sponsored by CytomX Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Interventions
- DRUG CX-904
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05387265
The ClinicalTrials.gov registry entry for NCT05387265 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CX-904 is the first listed.
NCT05387265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05387265 about?
NCT05387265 is a clinical study titled "A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors". The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
What is the current status of trial NCT05387265?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2022-05-16. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT05387265?
The interventions under investigation include: CX-904 (DRUG).
Who is sponsoring clinical trial NCT05387265?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.